Forward-looking statements

The information contained in this presentation is provided by Vaxil Bio Ltd. ("Vaxil") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of VAXIL or other financial products. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. The views, opinions and advice provided in this presentation reflect those of the individual presenters, and are provided for information purposes only. The presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of VAXIL nor its directors, officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. Except for statements of historical fact, this presentation contains certain “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements, including, among others, VAXIL’s future growth and development, the proposed plans of any of VAXIL’s equity holdings, as well as those risk factors identified in VAXIL’s Filing Statement and other disclosure documents available at www.sedar.com under VAXIL’s name. VAXIL undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person (as defined in Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”) ("U.S. Person"), or in any other jurisdiction in which such an offer would be illegal. VAXIL’s shares have not been and will not be registered under the Securities Act.
VAXIL TEAM

David Goren, MBA
CEO and Chairman
- Head, Pfizer Worldwide Strategy and BD
- CEO, Pfizer Israel
- President, AstraZeneca Israel
- VP Digital Health Strategy, AstraZeneca

Gadi Levin, CPA, MBA
CFO and Director
- CFO, LabStyle Innovations Ltd
- CFO, BriaCell Therapeutics Corp.
- VP / CFO of 2 investment houses

Mordechai Applebaum, PhD, MA
R&D Director
- Senior scientist and PM, Enlivex Therapeutics
- US Grant Consultant, FreeMind

Riva Kovjazin, MD, PhD
Senior Scientist
- Project leader, Center for Clinical Immunology
- Senior scientist at XTL Biopharmaceutical
Ari S. Kellen, MD, MBA
Director
• Senior partner, McKinsey & Co.
• EVP and GM, Bausch & Lomb US
• Advisory board, BioNanoSim (BNS)

Shawn Langer, MD
Director
• Senior partner, McKinsey & Co.
• Portfolio manager, BHMS Investments
## VAXIL IN BRIEF

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>01</strong></td>
<td>Targeting COVID-19 (infectious disease) and solid tumors</td>
</tr>
<tr>
<td><strong>02</strong></td>
<td>VaxHit™ target ID for signal peptides and mAbs</td>
</tr>
<tr>
<td><strong>03</strong></td>
<td>Clinical stage immunotherapy</td>
</tr>
<tr>
<td><strong>04</strong></td>
<td>5 Patent families</td>
</tr>
<tr>
<td><strong>05</strong></td>
<td>VXL traded on TSXV (2016)</td>
</tr>
<tr>
<td><strong>06</strong></td>
<td>Successful Phase 1/2a multiple myeloma clinical trial</td>
</tr>
<tr>
<td><strong>07</strong></td>
<td>Orphan designation for multiple myeloma (FDA / EMA)</td>
</tr>
<tr>
<td><strong>08</strong></td>
<td>P-ESBP In-licensing</td>
</tr>
</tbody>
</table>
Antigen specific multiple epitope vaccines

Recombinant Abs + companion diagnostic for ImMucin™

Antigen specific multiple epitope anti-infectives

P-ESBP (BGU)

COVID-19 (pending)
### VAXIL DEVELOPMENT OPPORTUNITIES & PRIORITIES

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Efficacy</th>
<th>Prophylaxis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Infectious Disease (COVID-19)</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
</tbody>
</table>
VAXIL PIPELINE

**Oncology**

- **MUC1-SP**
- **Additional SPs**
- **P-ESBP**
- **mAb program**

**ID**

- **Tuberculosis**
  - COVID-19 Vaccine
  - Other candidates

**Process Flow**

- Antigen Mining → VaxHit™ Proprietary Algorithm → Immune validation → Preclinical development → Clinical
SIGNAL PEPTIDE IN TRANSFORMED CELLS

Adapted from Kovjazin and Carmon, 2014
**SIGNAL PEPTIDE - VAXIL ADVANTAGE**

1. Densely populated with antigens (multi-antigen vaccine)
2. Wide HLA subclass restriction (applicable to heterogenous population)
3. Robust immune response (cellular and humoral)
4. HLA-independent exposure (circumventing tumor immune escape)
5. TAP-independent HLA loading (circumventing tumor immune escape)

Adapted from Kovjazin and Carmon, 2014
WHY IT WORKS: SIGNAL PEPTIDE - T CELL PROLIFERATION (IMMUNOGENICITY)

MUC1-SP (oncology)

Adapted from Kovjazin et al (2011, Vaccine)

TB SP (infectious disease)

Adapted from Kovjazin et al (2013, Clinical Vaccine Immunology)

PPD – purified protein derivative
TT – tetanus toxoid
**WHY IT WORKS - PART 2: T CELL ACTIVATION**

**MUC1-SP (oncology)**

- TNF-α (red)
- IFN-Gamma (blue)
- IL-2 (green)

**TB SP (infectious disease, VXL-211)**

- TNF-α
- INF-γ
- IL-2
- IL-4
- IL-12

Kovjazin et al (2011, Vaccine)

Adapted from Kovjazin et al (2013, Clinical Vaccine Immunology)
Feb - March 2020:

• Innovative candidate identified using proprietary VaxHit™ tool with potential activity against COVID-19 (alone or in combination)

• Preclinical (non-GMP) production completed

• Preclinical efficacy experiments designed and begun
Secure partnership for COVID-19 infected blood samples and experiments (including recovered patients); initiate experiments on these samples

Secure regulatory pathway, necessary data to clinical trial

Initiate GMP production

Explore additional funding options